Cargando…

Prognostic role and interaction of TERT promoter status, telomere length and MGMT promoter methylation in newly diagnosed IDH wild-type glioblastoma patients

BACKGROUND: The clinical relevance of promoter mutations and single nucleotide polymorphism rs2853669 of telomerase reverse transcriptase (TERT) and telomere length in patients with isocitrate dehydrogenase (IDH) wild-type glioblastoma (GBM) patients remains unclear. Moreover, some studies speculate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giunco, S., Padovan, M., Angelini, C., Cavallin, F., Cerretti, G., Morello, M., Caccese, M., Rizzo, B., d’Avella, D., Puppa, A.D., Chioffi, F., De Bonis, P., Zagonel, V., De Rossi, A., Lombardi, G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265608/ https://www.ncbi.nlm.nih.gov/pubmed/37230028 http://dx.doi.org/10.1016/j.esmoop.2023.101570

Ejemplares similares

Association between thyroid function and regorafenib efficacy in patients with relapsed wild-type IDH glioblastoma: a large multicenter study
por: Caccese, Mario, et al.
Publicado: (2023)

Newly Diagnosed Multifocal GBM: A Monocentric Experience and Literature Review
por: Baro, Valentina, et al.
Publicado: (2022)

Definition of the Prognostic Role of MGMT Promoter Methylation Value by Pyrosequencing in Newly Diagnosed IDH Wild-Type Glioblastoma Patients Treated with Radiochemotherapy: A Large Multicenter Study
por: Caccese, Mario, et al.
Publicado: (2022)

Cognitive Rehabilitation in Patients with Gliomas and Other Brain Tumors: State of the Art
por: Bergo, E., et al.
Publicado: (2016)

Regorafenib in Recurrent Glioblastoma Patients: A Large and Monocentric Real-Life Study
por: Lombardi, Giuseppe, et al.
Publicado: (2021)

The role of radiation therapy and systemic treatments in meningioma: The present and the future
por: Caccese, Mario, et al.
Publicado: (2023)

Patterns of gray and white matter functional networks involvement in glioblastoma patients: indirect mapping from clinical MRI scans
por: Sansone, Giulio, et al.
Publicado: (2023)

IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry
por: Yang, Pei, et al.
Publicado: (2015)

Clinical and Prognostic Implications of 1p/19q, IDH, BRAF, MGMT Promoter, and TERT Promoter Alterations, and Expression of Ki-67 and p53 in Human Gliomas
por: Yang, Zixi, et al.
Publicado: (2021)

Prognostic Impact of the Combination of MGMT Methylation and TERT Promoter Mutation in Glioblastoma
por: Tunthanathip, Thara, et al.
Publicado: (2021)

Perfusion CT detects alterations in local cerebral flow of glioma related to IDH, MGMT and TERT status
por: Wang, Ke, et al.
Publicado: (2021)

The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma
por: Diplas, Bill H., et al.
Publicado: (2018)

XGBoost Improves Classification of MGMT Promoter Methylation Status in IDH1 Wildtype Glioblastoma
por: Le, Nguyen Quoc Khanh, et al.
Publicado: (2020)

Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma
por: Chai, Ruichao, et al.
Publicado: (2021)

Myeloid Diagnostic and Prognostic Markers of Immune Suppression in the Blood of Glioma Patients
por: Del Bianco, Paola, et al.
Publicado: (2022)

Estimating the 95% confidence interval for survival gain between an experimental anti-cancer treatment and a control
por: Messori, Andrea, et al.
Publicado: (2017)

Clinical Management of Diffuse Low-Grade Gliomas
por: Lombardi, Giuseppe, et al.
Publicado: (2020)

Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma?
por: Teske, Nico, et al.
Publicado: (2021)

Immunohistochemical Expression of PD-L1 and IDH1 with Detection of MGMT Promoter Methylation in Astrocytoma
por: Hareedy, Amal Ahmed, et al.
Publicado: (2022)

Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives
por: Birzu, Cristina, et al.
Publicado: (2020)

Topographical Mapping of 436 Newly Diagnosed IDH Wildtype Glioblastoma With vs. Without MGMT Promoter Methylation
por: Incekara, Fatih, et al.
Publicado: (2020)

Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas
por: Killela, Patrick J., et al.
Publicado: (2014)

The interaction between TERT promoter mutation and MGMT promoter methylation on overall survival of glioma patients: a meta-analysis
por: Vuong, Huy Gia, et al.
Publicado: (2020)

Prognostic Stratification of GBMs Using Combinatorial Assessment of IDH1 Mutation, MGMT Promoter Methylation, and TERT Mutation Status: Experience from a Tertiary Care Center in India()
por: Purkait, Suvendu, et al.
Publicado: (2016)

Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO)
por: Padovan, Marta, et al.
Publicado: (2021)

Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide
por: van Nifterik, K A, et al.
Publicado: (2010)

Validation of the Comprehensive Geriatric Assessment as a Predictor of Mortality in Elderly Glioblastoma Patients
por: Lombardi, Giuseppe, et al.
Publicado: (2019)

SYST-20 TARGETED THERAPY MATCHED TO GENOMIC ALTERATIONS (BRAFV600E, NTRK, FGFR, ROS1, PIK3CA, PTEN) IN PATIENTS WITH RECURRENT IDH WILDTYPE GLIOBLASTOMA: A REAL-LIFE COHORT ANALYSIS FROM VENETO INSTITUTE OF ONCOLOGY, PADUA (ITALY)
por: Padovan, Marta, et al.
Publicado: (2023)

Prognostic impact of PDGFRA gain/amplification and MGMT promoter methylation status in patients with IDH wild-type glioblastoma
por: Higa, Nayuta, et al.
Publicado: (2022)

Favorable role of IDH1/2 mutations aided with MGMT promoter gene methylation in the outcome of patients with malignant glioma
por: Pandith, Arshad A, et al.
Publicado: (2020)

Immune-Related lncRNA Risk Signatures Predict Survival of IDH Wild-Type and MGMT Promoter Unmethylated Glioblastoma
por: Li, Xiaozhi, et al.
Publicado: (2020)

MGMT Promoter Methylation and IDH1 Mutations Do Not Affect [(18)F]FDOPA Uptake in Primary Brain Tumors
por: Cimini, Andrea, et al.
Publicado: (2020)

MGMT gene promoter methylation by pyrosequencing method correlates volumetric response and neurological status in IDH wild-type glioblastomas
por: Hosoya, Tomohiro, et al.
Publicado: (2022)

Prediction of the Molecular Subtype of IDH Mutation Combined with MGMT Promoter Methylation in Gliomas via Radiomics Based on Preoperative MRI
por: Sha, Yongjian, et al.
Publicado: (2023)

Mismatch-Repair Protein Expression in High-Grade Gliomas: A Large Retrospective Multicenter Study
por: Caccese, Mario, et al.
Publicado: (2020)

The Association Between the Extent of Glioblastoma Resection and Survival in Light of MGMT Promoter Methylation in 326 Patients With Newly Diagnosed IDH-Wildtype Glioblastoma
por: Incekara, Fatih, et al.
Publicado: (2020)

Relationship between IDH1/2 and TERT promoter mutation and the prognosis of human glioma patients
por: Liu, Xipeng, et al.
Publicado: (2023)

The value of MGMT promote methylation and IDH-1 mutation on diagnosis of pseudoprogression in patients with high-grade glioma: A meta-analysis
por: Zhou, Min, et al.
Publicado: (2019)

The Impact of IDH1 Mutation and MGMT Promoter Methylation on Recurrence-Free Interval in Glioblastoma Patients Treated With Radiotherapy and Chemotherapeutic Agents
por: Kurdi, Maher, et al.
Publicado: (2021)

First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed MGMT promoter methylated IDH wildtype glioblastoma
por: Lazaridis, Lazaros, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_scnsg5siv8lenmeht7jo2ejb48